4种高脂血症治疗方案的成本-效果分析  

Cost-effectiveness Analysis of Four Therapeutic Schemes for Hyperlipidemia

作　　者：张德根 

机构地区：[1]浙江省桐乡市第一人民医院,桐乡314500

出　　处：《海峡药学》2005年第6期158-160,共3页Strait Pharmaceutical Journal

摘　　要：目的探讨4种口服给药方案治疗高脂血症的经济效果。方法将130例患者为4组,A组给予脂必妥,B组给予非诺贝特,C组给予烟酸肌醇酯,D组组给予辛伐他汀,以药物经济学的成本-效果法分析4种方案。结果A、B、D方案的有效率相当,且明显高于C方案。4种方案的成本-效果比分别为1.16、3.38、0.50、3.42,敏感度分析成本-效果比分别为0.99、2.87、0.43、2.91。结论A方案在4种方案中最佳。OBJECTIVE To evaluate the economic efficiency of four oral administration schemes in treatment of hyperlipidemia. METHODS 130 patients with hyperlipidemia were divided into four groups： group A, Zhibituo,group B, Fenofibrate and group C, Inositol nicotinate, group D, Simvastatin. Data was evaluated using the pharmacoeconimic cost-effectiveness analysis. RESULTS The effective rate in group A was comparable to that in group B and group D. The effectives rate in group C was lower. The cost-effectiveness ratios of A, B,C, D were 1.16,3.38,0. 50,3.42, respectively. Using sensitivity analysis, the cost-effectiveness ratios were 0. 99,2. 87,0.43,2.91,respectively. CONCLUSION Among the four schemes,scheme A was the best one.

关 键 词：脂必妥 非诺贝特 烟酸肌醇酯 辛伐他汀 高脂血症 成本-效果 

分 类 号：F407.7[经济管理—产业经济]